- Home
- ELWT vs SNTI Comparison
ELWT vs SNTI Comparison
Compare ELWT & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELWT | SNTI |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 53.6M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELWT | SNTI |
|---|---|---|
| Price | $5.88 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $9.00 |
| AVG Volume (30 Days) | 54.3K | ★ 353.3K |
| Earning Date | 02-15-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,251,000.00 | N/A |
| Revenue This Year | $167.76 | N/A |
| Revenue Next Year | $22.42 | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 416.21 | N/A |
| 52 Week Low | $4.11 | $1.03 |
| 52 Week High | $8.75 | $5.10 |
Technical Indicators
Market Signals| Indicator | ELWT | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 35.19 |
| Support Level | N/A | $1.04 |
| Resistance Level | N/A | $1.16 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.